Navigation Links
Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
Date:3/26/2009

SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Future Leaders in the Biotech Industry conference on Thursday, April 2, 2009 at 2:00 p.m. EDT (11:00 a.m. PDT). The conference is being held at the Millennium Broadway Hotel in New York City.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through April 16, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Tooth decay is ... showing active signs of the disease. The World Health Organization ... nearly 100% of adults have cavities. What are the long-term ... is showing a strong connection between the oral bacterial imbalance ... this disease so rampant, yet it is also 100% preventable? ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... , , SOUTH PLAINFIELD, ... the initiation of a Phase 3 trial of ataluren (formerly ... mutation cystic fibrosis (nmCF). Patients with CF lack adequate ... a chloride channel necessary for normal function of the lung, ...
... , , INDIANAPOLIS, Sept. 10 ... Advanced lithium-ion battery maker EnerDel, Inc. today named Richard L. Stanley ... global manufacturing and management experience and a distinguished record of creating ... appointments designed to position EnerDel for continued success in the next ...
... , OXFORD, England, September ... Watkins as Head of the Product & Portfolio,Strategy ... Senior Advisors,and Analysts. , ... "We are,delighted to welcome Nikki to PharmaVentures. Our ...
Cached Biology Technology:PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6Lithium-Ion Battery Maker Names New President 2Lithium-Ion Battery Maker Names New President 3Lithium-Ion Battery Maker Names New President 4Lithium-Ion Battery Maker Names New President 5Lithium-Ion Battery Maker Names New President 6PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy 2
(Date:5/16/2013)... NEW YORK , May 16, 2013 ... market research report is available in its ... Market Forecast & Opportunities, 2018 ... data protection and old security practises such ... driven the growth of biometric technologies in ...
(Date:5/15/2013)... gout risk, new research reveals that vitamin C, also ... levels to a clinically significant degree in patients with ... with allopurinol, appears to have a weak effect on ... the results published in the American College of Rheumatology ... Gout is an inflammatory arthritis that causes excruciating pain ...
(Date:5/15/2013)... to date to examine the efficacy of PARP inhibitor ... breast and ovarian cancer, the oral drug olaparib was ... cancers. Results of the study, led by researchers from ... Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, ... Oncology,s annual meeting in Chicago in early June (Abstract ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... MADISON, WI, September 29, 2008 A plot of ... 110 years of sustainable farming practices can produce similar ... In 1896, Professor J.F. Duggar at the Agricultural ... an experiment to test his theories that sustainable cotton ...
... video clip of Leonard Kleinrock showing his contributions to ... George W. Bush will award the National Medals of ... leading researchers, inventors and innovators, at a ceremony in ... a.m. on Monday, September 29, 2008. Reporters interested in ...
... that inexpensive device boosts fuel economy by up to 20 ... prices, researchers in Pennsylvania are reporting results of laboratory tests ... to a car engine,s fuel injector can boost gas mileage ... precious miles per gallon, they say. Their study is scheduled ...
Cached Biology News:Experiment demonstrates 110 years of sustainable agriculture 28 National Medals of Science awardees to be honored at gala, then the White House 28 National Medals of Science awardees to be honored at gala, then the White House 38 National Medals of Science awardees to be honored at gala, then the White House 48 National Medals of Science awardees to be honored at gala, then the White House 58 National Medals of Science awardees to be honored at gala, then the White House 68 National Medals of Science awardees to be honored at gala, then the White House 78 National Medals of Science awardees to be honored at gala, then the White House 8American Chemical Society's Weekly PressPac -- Sept. 24, 2008 2American Chemical Society's Weekly PressPac -- Sept. 24, 2008 3American Chemical Society's Weekly PressPac -- Sept. 24, 2008 4American Chemical Society's Weekly PressPac -- Sept. 24, 2008 5American Chemical Society's Weekly PressPac -- Sept. 24, 2008 6American Chemical Society's Weekly PressPac -- Sept. 24, 2008 7American Chemical Society's Weekly PressPac -- Sept. 24, 2008 8
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... is a G1 cyclin required for G1-phase ... a proto-oncogene. cyclin D2 can phosphorylate ... Species Reactivity: Human, Mouse, and Rat. ... is particularly well suited for neutralization of ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: